DMAAR
Drugs Made In America Acquisition Corp.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 0 added (0 new), 2 trimmed or exited.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| Hudson Bay Capital Management LP | TRIM | $83.5K |
| WOLVERINE ASSET MANAGEMENT LLC | TRIM | $51.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
3 filings · 1 bullish · 1 bearish · 1 neutral- NEUTRAL 8-KMay 5, 2026
DMAA, a SPAC, entered into a definitive merger agreement with private AI/analytics company Power…
Monitor for the filing of the S-4 registration statement and subsequent redemption levels; the deal's success hinges on PAGC's ability to deliver verified revenue contracts meeting the valuation…
- BEARISH 8-KMay 1, 2026
Drugs Made In America Acquisition Corp. (DMAAR) held an extraordinary general meeting on April 27…
The 28.2% redemption rate is a strong negative signal — nearly a third of shareholders chose to exit rather than wait for a deal. The remaining trust is now materially smaller, reducing the SPAC's…
- BULLISH 8-KApr 8, 2026
Drugs Made In America Acquisition Corp. (DMAAR) entered into a non-binding letter of intent to…
Monitor for definitive business combination agreement and Form S-4 filing, which will provide final terms, including share exchange ratios and PIPE financing details. The $25M-$50M minimum cash…
All DMAAR filing & press-release reports (3)
- 8-K reportMay 5, 2026
- 8-K reportMay 1, 2026
- 8-K reportApr 8, 2026